Karyopharm Therapeutics Files 8-K with Material Agreements & Financial Updates

TL;DR

Karyopharm dropped an 8-K detailing new deals, financial results, and exec changes. Big day for the stock.

AI Summary

Karyopharm Therapeutics Inc. announced on October 7, 2025, the entry into a material definitive agreement. The company also reported on its results of operations and financial condition, and disclosed the creation of a direct financial obligation. Additionally, Karyopharm addressed unregistered sales of equity securities, departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also included a Regulation FD disclosure and other events, along with financial statements and exhibits.

Why It Matters

This 8-K filing provides crucial updates on Karyopharm's financial health, strategic agreements, and corporate governance, which are important for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — The filing covers multiple significant events including material agreements, financial obligations, and equity sales, which can introduce volatility and uncertainty.

Key Players & Entities

• Karyopharm Therapeutics Inc. (company) — Registrant
• October 7, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-36167 (identifier) — SEC File Number

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
• $100 million — g Transactions provide the Company with $100 million of financial flexibility and additional
• $67.5 million — clude the following key components: (i) $67.5 million in financial flexibility and new capita
• $27.5 million — ng senior secured lenders consisting of $27.5 million in new term loan borrowings and new con
• $25 million — and new convertible debt, approximately $25 million of near-term deferrals of interest and
• $15.0 million — payments, and a temporary reduction of $15.0 million in the Company's minimum liquidity cove
• $24.25 million — s of common stock; (iii) an exchange of $24.25 million aggregate principal amount of the Compa
• $8.75 million — hase common stock for gross proceeds of $8.75 million. The Company intends to use the proceed
• $36.0 m — roceeds to the Company of approximately $36.0 million, before payment of any transactio
• $112.5 million — ing Transactions, the Company will have $112.5 million outstanding under its senior secured te
• $103.5 million — red convertible notes due October 2028, $103.5 million aggregate principal amount of 9.00% sen
• $0.25 million — tible notes due May 2029, approximately $0.25 million aggregate principal amount of 3.00% sen
• $116.2 million — notes maturing on October 15, 2025 and $116.2 million of maximum remaining payments payable u
• $6.64 — common stock with an exercise price of $6.64 per share, a 15% premium to the Nasdaq
• $16.50 — rants to purchase 3,068,417 shares from $16.50 to $6.64 per share. Following consummat

Filing Documents

• d940170d8k.htm (8-K) — 100KB
• d940170dex991.htm (EX-99.1) — 33KB
• g940170g1007002448441.jpg (GRAPHIC) — 4KB
• 0001193125-25-233983.txt ( ) — 276KB
• kpti-20251007.xsd (EX-101.SCH) — 3KB
• kpti-20251007_lab.xml (EX-101.LAB) — 18KB
• kpti-20251007_pre.xml (EX-101.PRE) — 11KB
• d940170d8k_htm.xml (XML) — 4KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 7, 2025 Karyopharm Therapeutics Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36167 26-3931704 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 85 Wells Avenue , 2nd Floor Newton , Massachusetts 02459 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (617) 658-0600 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item1.01 Entry into a Material Definitive Agreement. On October 7, 2025, Karyopharm Therapeutics Inc. (the "Company") entered into a series of transactions with its term loan lenders, holders of its outstanding convertible notes and other investors to provide financial flexibility, additional working capital and equitize maturing notes (collectively, the "Financing Transactions"). The Company expects the Financing Transactions to enable the Company to fund its current operating plans into the second quarter of 2026. As described in more detail below, the Financing Transactions provide the Company with $100 million of financial flexibility and additional capital and include the following key components: (i) $67.5 million in financial flexibility and new capital in a series of transactions with existing senior secured lenders consisting of $27.5 million in new term loan borrowings and new convertible debt, approximately $25 million of near-term deferrals of interest and royalty payments, and a temporary reduction of $15.0 million in the Company's minimum liquidity covenant; (ii) an exchange of $15.0 million aggregate principal amount of the Company's convertible notes due 2029 for shares of common stock; (iii) an exchange of $24.25 million aggregate principal amount of the Company's convertible notes due October 15, 2025 for shares of common stock and warrants to purchase shares of common stock; and (iv) a private placement of shares of common stock and warrants to purchase common stock for gross proceeds of $8.75 million. The Company intends to use the proceeds described above to pay transaction expenses and for general corporate purposes, including to support the Company's ongoing and planned clinical trial activities. The Company expects to consummate the Financing Transactions on or around October 10, 2025 (the "Closing Date"). The Company expects the Financing Transactions to result in aggregate cash proceeds to the Company of approximately $36.0 million, before payment of any transaction expenses. Following consummation of the Financing Transactions, the Company will have $112.5 million outstanding under its senior secured term loan with a maturity date in May 2028, $15.0 million aggregate principal amount of 9.00% senior secured convertible notes due October 2028, $103.5 million aggregate principal amount of 9.00% senior secured convertible notes due May 2029, approximately $0.25 million aggregate principal amount of 3.00% senior convertible notes maturing on October 15, 2025 and $116.2 million of maximum remaining payments payable under its revenue interest financing agreement. In connection with the Financing Transactions, the Company will issue an aggregate of 7,223,982 newly issued shares of common stock, newly issued pre-funded warrants to purchase an aggregate of 2,913,136 shares of common stock, and newly issued warrants to purchase an aggregate of 5,918,358 shares of

View Full Filing

View this 8-K filing on SEC EDGAR